Galapagos NV Company Profile (NASDAQ:GLPG)

About Galapagos NV (NASDAQ:GLPG)

Galapagos NV logoGalapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GLPG
  • CUSIP: N/A
  • Web: www.glpg.com
Capitalization:
  • Market Cap: $4.11927 billion
  • Outstanding Shares: 46,256,000
Average Prices:
  • 52 Week Range: $51.91 - $94.88
P/E:
  • Trailing P/E Ratio: 771.32
  • Foreward P/E Ratio: -61.01
  • P/E Growth: 0.00
Profitability:
  • Net Margins: 2.11%
  • Return on Equity: 0.48%
  • Return on Assets: 0.33%
Debt:
  • Current Ratio: 7.75%
  • Quick Ratio: 7.75%
Misc:
  • Beta: 1.78
 
Frequently Asked Questions for Galapagos NV (NASDAQ:GLPG)

What is Galapagos NV's stock symbol?

Galapagos NV trades on the NASDAQ under the ticker symbol "GLPG."

Where is Galapagos NV's stock going? Where will Galapagos NV's stock price be in 2017?

7 analysts have issued twelve-month target prices for Galapagos NV's shares. Their predictions range from $64.00 to $121.00. On average, they anticipate Galapagos NV's stock price to reach $94.80 in the next twelve months. View Analyst Ratings for Galapagos NV.

What are analysts saying about Galapagos NV stock?

Here are some recent quotes from research analysts about Galapagos NV stock:

  • 1. BTIG Research analysts commented, "Supports Thesis for Minimal Function CF Patients Yesterday, Vertex (VRTX, Not Rated) provided top-line results of the first triplet combination studies for Cystic Fibrosis patients with minimal function mutations, which represents 1/3 of the total patient population. Importantly, the triplet combinations also demonstrated improvements with the F508del homozygous population that exceed the clinical benefit of Orkambi. Overall, this first data for triplet therapies provides positive support for the use of two CFTR correctors within one daily regimen. The results from VRTX’s studies are positive for GLPG’s efforts conceptually, but given GLPG’s limited dataset to date, we continue to think that efforts within CF are a ‘show-me’ story. We maintain our Buy rating and $98 PT.   X-440 and VX-152 Triplet Combinations set a new hurdle rate for clinical efficacy: Although the timespans were relatively short, with 29 days studied with VX-440 and 15 days with VX-152, the +9.5% and +7.3% respective improvements of ppFEV1 are impressive within the F508del homozygous population given the study design had a 4 week run-in period with tezacaftor and ivacaftor. Furthermore, the statistically significant improvements in ppFEV1 in both VX-440 and VX-152 studies within the F508del/Min patient population is unprecedented, underscored by the previous failure of the tezacaftor + ivacaftor combination study." (7/20/2017)
  • 2. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (7/14/2017)
  • 3. Cowen and Company analysts commented, "GLPG provided a broad pipeline update at an R&D day." (6/21/2017)
  • 4. Instinet analysts commented, "We are initiating coverage on Galapagos (GLPG) with a buy rating and $87 target price. We believe the company's rapidly advancing cystic fibrosis (CF) pipeline, partnered with AbbVie, will drive shares higher in the next 12 months. We also anticipate an increasing focus on filgotinib's opportunity in Crohn's disease, and ulcerative colitis (UC) in Phase 3 trials, may lead to upside in shares over the next 12-months. In our view, the current valuation is predominantly supported primarily by the blockbuster opportunity for the company's lead oral JAK1 inhibitor, filgotinib (partnered with Gilead), for the treatment of rheumatoid arthritis." (3/1/2017)

Are investors shorting Galapagos NV?

Galapagos NV saw a increase in short interest in June. As of June 15th, there was short interest totalling 805,865 shares, an increase of 39.5% from the May 31st total of 577,527 shares. Based on an average daily volume of 171,148 shares, the short-interest ratio is presently 4.7 days.

Who are some of Galapagos NV's key competitors?

Who are Galapagos NV's key executives?

Galapagos NV's management team includes the folowing people:

  • Onno van de Stolpe, Chief Executive Officer, Executive Director
  • Bart Filius, Chief Financial Officer
  • Andre Hoekema, Senior Vice President - Corporate Development
  • Piet Wigerinck, Chief Scientific Officer
  • Rajesh Parekh, Non-Executive Chairman of the Board
  • Harrold van Barlingen, Non-Executive Director
  • Katrine Bosley, Independent Non-Executive Director
  • Werner Cautreels, Non-Executive Independent Director
  • Christine Mummery, Non-Executive Independent Director

When did Galapagos NV IPO?

(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who owns Galapagos NV stock?

Galapagos NV's stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.00%), US Bancorp DE (0.00%), P.A.W. Capital Corp (0.03%), Eqis Capital Management Inc. (0.00%), Aperio Group LLC (0.00%) and Bank of Montreal Can (0.00%). View Institutional Ownership Trends for Galapagos NV.

Who sold Galapagos NV stock? Who is selling Galapagos NV stock?

Galapagos NV's stock was sold by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp and Peregrine Capital Management LLC. View Insider Buying and Selling for Galapagos NV.

Who bought Galapagos NV stock? Who is buying Galapagos NV stock?

Galapagos NV's stock was acquired by a variety of institutional investors in the last quarter, including US Bancorp DE, Eqis Capital Management Inc., Acadian Asset Management LLC, Aperio Group LLC and Bank of Montreal Can. View Insider Buying and Selling for Galapagos NV.

How do I buy Galapagos NV stock?

Shares of Galapagos NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galapagos NV's stock price today?

One share of Galapagos NV stock can currently be purchased for approximately $81.76.


MarketBeat Community Rating for Galapagos NV (NASDAQ GLPG)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Galapagos NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Galapagos NV (NASDAQ:GLPG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $94.80 (15.95% upside)

Analysts' Ratings History for Galapagos NV (NASDAQ:GLPG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/20/2017BTIG ResearchReiterated RatingBuy$98.00HighView Rating Details
7/7/2017Janney Montgomery ScottUpgradeSell -> NeutralLowView Rating Details
6/22/2017InstinetReiterated RatingBuy$121.00 -> $108.00LowView Rating Details
6/22/2017NomuraLower Price TargetBuy$108.00 -> $121.00LowView Rating Details
6/21/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
5/1/2017Stifel NicolausBoost Price TargetHold$65.00 -> $83.00LowView Rating Details
10/18/2016Goldman Sachs Group, Inc. (The)UpgradeNeutral -> BuyN/AView Rating Details
6/17/2016Credit Suisse GroupReiterated RatingHold$48.00N/AView Rating Details
5/2/2016Morgan StanleyReiterated RatingBuy$89.00N/AView Rating Details
12/17/2015Bryan, Garnier & CoBoost Price TargetBuy$52.00 -> $64.00N/AView Rating Details
12/8/2015KBC SecuritiesUpgradeBuyN/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Galapagos NV (NASDAQ:GLPG)
Earnings by Quarter for Galapagos NV (NASDAQ:GLPG)
Earnings History by Quarter for Galapagos NV (NASDAQ GLPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2015Q3($0.80)$11.46 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galapagos NV (NASDAQ:GLPG)
Current Year EPS Consensus Estimate: $-2.28 EPS
Next Year EPS Consensus Estimate: $-1.34 EPS

Dividends

Dividend History for Galapagos NV (NASDAQ:GLPG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galapagos NV (NASDAQ:GLPG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Galapagos NV (NASDAQ:GLPG)
Latest Headlines for Galapagos NV (NASDAQ:GLPG)
Source:
DateHeadline
americanbankingnews.com logoGalapagos NV (NASDAQ:GLPG) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 24 at 6:52 PM
nasdaq.com logoGalapagos (GLPG) Looks Good: Stock Adds 6.2% in Session - Nasdaq
www.nasdaq.com - July 22 at 12:32 AM
americanbankingnews.com logoGalapagos NV (GLPG) Receives Buy Rating from BTIG Research
www.americanbankingnews.com - July 20 at 8:43 AM
reuters.com logoVertex Pharma shares hit life high as cystic fibrosis data wows
www.reuters.com - July 19 at 7:45 PM
finance.yahoo.com logoVertex Hits Record High On Results Of Cystic Fibrosis Trial
finance.yahoo.com - July 19 at 7:45 PM
americanbankingnews.com logoGalapagos NV (NASDAQ:GLPG) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 16 at 12:58 PM
americanbankingnews.com logoEnanta Pharmaceuticals (ENTA) and Galapagos NV (GLPG) Head-To-Head Review
www.americanbankingnews.com - July 16 at 8:08 AM
seekingalpha.com logoTiGenix: This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come
seekingalpha.com - July 13 at 12:47 AM
americanbankingnews.com logoGalapagos NV (NASDAQ:GLPG) Upgraded to "Neutral" by Janney Montgomery Scott
www.americanbankingnews.com - July 7 at 11:46 PM
americanbankingnews.com logo$26.50 Million in Sales Expected for Galapagos NV (GLPG) This Quarter
www.americanbankingnews.com - July 7 at 11:36 AM
americanbankingnews.com logoGalapagos NV (NASDAQ:GLPG) Expected to Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - July 5 at 10:18 PM
finanznachrichten.de logoGalapagos NV: New Phase 2 study with filgotinib in non-infectious uveitis
www.finanznachrichten.de - July 5 at 7:43 PM
streetinsider.com logoGalapagos NV (GLPG) Announces New Phase II Study With Filgotinib In Non-infectious Uveitis - StreetInsider.com
www.streetinsider.com - July 5 at 7:40 AM
americanbankingnews.com logoGalapagos NV (GLPG) Short Interest Up 39.5% in June
www.americanbankingnews.com - June 30 at 7:22 AM
americanbankingnews.com logoGalapagos NV (GLPG) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - June 27 at 6:40 PM
americanbankingnews.com logoGalapagos NV (GLPG) Receives "Buy" Rating from Instinet
www.americanbankingnews.com - June 22 at 11:40 PM
americanbankingnews.com logoGalapagos NV (GLPG) Given New $121.00 Price Target at Nomura
www.americanbankingnews.com - June 22 at 1:38 PM
streetinsider.com logoGalapagos NV (GLPG) PT Lowered to $108 at Instinet Following the company's R&D Day - StreetInsider.com
www.streetinsider.com - June 22 at 9:27 AM
americanbankingnews.com logoGalapagos NV (GLPG) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - June 21 at 9:26 PM
seekingalpha.com logoGalapagos updates investors in R&D programs
seekingalpha.com - June 21 at 4:13 AM
streetinsider.com logoGalapagos NV (GLPG) Reports Increase in Share Capital Through Warrant Exercises
www.streetinsider.com - June 21 at 4:13 AM
streetinsider.com logoGalapagos NV (GLPG) Reports Increase in Share Capital Through Warrant Exercises - StreetInsider.com
www.streetinsider.com - June 20 at 6:13 PM
feeds.benzinga.com logoGalapagos' R&D Update 2017: rapidly advancing our product candidates
feeds.benzinga.com - June 20 at 2:04 AM
streetinsider.com logoBTIG Starts Galapagos NV (GLPG ) at Buy
www.streetinsider.com - June 19 at 9:31 PM
americanbankingnews.com logoZacks: Analysts Anticipate Galapagos NV (GLPG) Will Post Quarterly Sales of $26.50 Million
www.americanbankingnews.com - June 11 at 7:46 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Galapagos NV (GLPG) to Announce -$0.68 Earnings Per Share
www.americanbankingnews.com - June 9 at 10:30 PM
americanbankingnews.com logoGalapagos NV (GLPG) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - June 2 at 8:24 AM
americanbankingnews.com logoGalapagos NV (GLPG) Upgraded to "C" by TheStreet
www.americanbankingnews.com - May 19 at 2:50 PM
finanznachrichten.de logoGalapagos NV: Galapagos creates new warrant plan
www.finanznachrichten.de - May 17 at 10:27 PM
americanbankingnews.com logoGalapagos NV (GLPG) Expected to Announce Quarterly Sales of $26.5 Million
www.americanbankingnews.com - May 17 at 10:54 AM
feeds.benzinga.com logoSeven abstracts on filgotinib accepted by EULAR 2017
feeds.benzinga.com - May 15 at 4:46 PM
americanbankingnews.com logoZacks: Brokerages Expect Galapagos NV (GLPG) Will Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - May 15 at 12:30 PM
americanbankingnews.com logoShort Interest in Galapagos NV (GLPG) Rises By 16.2%
www.americanbankingnews.com - May 13 at 9:20 AM
finanznachrichten.de logoGalapagos NV: Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017
www.finanznachrichten.de - May 8 at 5:13 PM
americanbankingnews.com logoGalapagos NV (GLPG) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 8 at 12:48 PM
feeds.benzinga.com logoGalapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017
feeds.benzinga.com - May 7 at 12:04 PM
americanbankingnews.com logoFY2017 EPS Estimates for Galapagos NV (GLPG) Reduced by Jefferies Group
www.americanbankingnews.com - May 4 at 3:34 PM
finance.yahoo.com logoGalapagos NV :GLPG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 4 at 12:08 PM
americanbankingnews.com logoGalapagos NV (GLPG) Given Daily News Sentiment Rating of 0.03
www.americanbankingnews.com - May 2 at 6:36 PM
americanbankingnews.com logoStifel Nicolaus Reaffirms Hold Rating for Galapagos NV (GLPG)
www.americanbankingnews.com - May 1 at 1:40 PM
streetinsider.com logoGalapagos NV (GLPG): Filgotinib Progressing Nicely - Stifel - StreetInsider.com
www.streetinsider.com - May 1 at 11:56 AM
americanbankingnews.com logoGalapagos NV (GLPG) Given News Impact Rating of 0.07
www.americanbankingnews.com - April 29 at 4:18 PM
finanznachrichten.de logoGalapagos NV: Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
www.finanznachrichten.de - April 29 at 9:34 AM
finance.yahoo.com logoGalapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
finance.yahoo.com - April 29 at 9:33 AM
finance.yahoo.com logoETFs with exposure to Galapagos NV : April 28, 2017
finance.yahoo.com - April 28 at 6:30 PM
americanbankingnews.com logoJanney Montgomery Scott Downgrades Galapagos NV (GLPG) to Sell
www.americanbankingnews.com - April 28 at 7:16 AM
finance.yahoo.com logoGalapagos reports first quarter 2017 results
finance.yahoo.com - April 27 at 6:03 PM
streetinsider.com logoGalapagos NV (GLPG) Reports Phase 2 Proof-of-Concept Study with Filgotinib in CLE - StreetInsider.com
www.streetinsider.com - April 27 at 8:03 AM
streetinsider.com logoGalapagos NV (GLPG) Reports Phase 2 Proof-of-Concept Study with Filgotinib in CLE
www.streetinsider.com - April 26 at 7:56 PM
americanbankingnews.com logo$31.81 Million in Sales Expected for Galapagos NV (GLPG) This Quarter
www.americanbankingnews.com - April 26 at 10:52 AM

Social

Chart

Galapagos NV (GLPG) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff